industry |
[서울=뉴스핌] Reporter Kim Yang-seop = Raphas (CEO Jeong Do-hyun) conducted a challenge experiment on Mycobacterium tuberculosis using a new tuberculosis vaccine candidate, Mycobacteria Paragordonea (Mpg), a non-tuberculous mycobacteria (evaluation of defense ability by directly infecting vaccinated animals with the virus) ) on the 3rd.
In March 2021, as part of the development of a tuberculosis booster vaccine under development through a national project of the Vaccine Commercialization Technology Development Project organized by the Ministry of Health and Welfare, Raphas confirmed the animal efficacy evaluation in the economical cultivation method of strains and microneedle formulation research.
Raphas’ Mpg tuberculosis vaccine is a method of inoculating live bacteria in the same way as the existing BCG vaccine, but unlike the BCG vaccine, it does not proliferate at 37 ° C, which is the human basal body temperature, so it is less concerned about side effects than the existing BCG live bacteria vaccine. The company explained that it is a vaccine candidate material that has confirmed a higher cellular immunity effect than BCG vaccine through animal experiments.
Through this challenge inoculation experiment, the ability of the Mpg strain to fight Mycobacterium tuberculosis was confirmed, and the number of Mycobacterium tuberculosis bacteria remaining in the lungs of animals was about 20 times lower than that of the BCG vaccinated group. It was explained that this was the result of confirming that cells immunized with the Mpg tuberculosis vaccine strain could block infection and proliferation of Mycobacterium tuberculosis.
BCG vaccine is prescribed using a metal frame, and depending on the pretreatment of the vaccine and the skill of the medical staff, loss of antigen may occur during administration, whereas Raphas’ microneedle patch is convenient to attach and can prevent loss of antigen. There are advantages to
An official from Raphas said, “The microneedle formulation loaded with the Mpg tuberculosis vaccine strain has secured the stability of live cells suitable for the WHO tuberculosis vaccine guidelines.” “We are preparing the study for clinical trials,” he said.
Meanwhile, attention is focusing on whether the development of the new Mpg tuberculosis vaccine under development by Raphas can contribute to domestic vaccine self-sufficiency at a time when BCG vaccine, one of Korea’s essential vaccinations, is entirely dependent on imports.
2023-05-03 00:30:00
#Raphas #Confirmation #Mpg #tuberculosis #vaccines #ability #protect #tuberculosis #bacillus
